Losartan and Nivolumab in Combination With FOLFIRINOX and SBRT in Localized Pancreatic Cancer

This research study is a Phase II clinical trial. Phase II clinical trials test the safety
and effectiveness of an investigational intervention to learn whether the intervention works
in treating a specific disease. "Investigational" means that the intervention is being
studied.

The FDA (the U.S. Food and Drug Administration) has approved FOLFIRINOX as a treatment option
for this disease.

The FDA has not approved losartan or nivolumab for this specific disease but they have been
approved for other uses.

FOLFIRINOX is a combination of 4 chemotherapy agents that may help shrink your tumor before
surgery. Losartan is a drug that is used to lower blood pressure. Nivolumab is an antibody (a
cell that attaches to other cells to fight off infection) that may cause programmed cell
death of cancer cells. Radiation therapy is believed to increase the likelihood of response
of immunotherapy (the prevention/treatment of a disease through an immune response).

Inclusion Criteria:

- Histologically confirmed localized pancreatic adenocarcinoma; borderline/potentially
resectable or locally advanced.

- Borderline resectable is defined by the NCCN as tumors with venous involvement of the
SMV/portal vein demonstrated tumor abutment with or without impingement and narrowing
of the lumen, either tumor thrombus or encasement but with suitable vessel proximal
and distal to the area of vessel involvement, allowing for safe resection or
reconstruction; gastroduodenal artery encasement up to the hepatic artery with either
short segment encasement or direct abutment of the hepatic artery, without extension
to the celiac axis; or tumor abutment of the SMA not to exceed greater than 180
degrees of the circumference of the vessel wall. Tumors involving retroperitoneal
structures that can be surgically removed (i.e. kidney), will also be included.

- Localized is defined as no extrapancreatic disease, no evidence (on CT) of involvement
of the celiac axis or SMA, no evidence (CT or MRI) of occlusion of the SMV or SMPV
confluence, no evidence of gross peritoneal or distant metastases on staging
laparoscopy or laparotomy.

- Locally advanced unresectable disease is defined by the NCCN as: Tumors of the head
that have greater than 180 degrees of SMA encasement or any celiac abutment,
unreconstructable SMV or portal occlusion, or aortic invasion or encasement. Tumors of
the body with SMA or celiac encasement of greater than 180 degrees, unreconstructable
SMV or portal occlusion, or aortic invasion. Tumors of the tail with SMA or celiac
encasement of greater than 180 degrees. Irrespective of location, all tumors with
evidence of nodal metastasis outside of the resection field are deemed unresectable.

- Age > 18 years

- ECOG performance status 0-1

- Baseline Systolic Blood Pressure (SBP) > 100 mm Hg. This is based on the average of
two values - separate seated, resting measurements taken five minutes apart. BP does
not need to be checked in both arms unless a reading is below 110 mm Hg, in which case
the other arm can be checked as well. If BP is checked in both arms, the higher value
is deemed accurate for calculating the average.

- Normal organ and marrow function as defined below:

- absolute neutrophil count ≥ 1,500/mm3

- platelets ≥ 100,000/mm3

- total bilirubin ≤ 1.5 x institutional upper limit of normal if no biliary
stenting has been done OR 2.0 x upper limit of normal if patient is s/p biliary
stenting OR two down trending values

- AST(SGOT)/ALT(SGPT) ≤ 2.5 × institutional upper limit of normal

- Potassium (not hemolyzed) < 5 mmol/L

- creatinine ≤ 1.5 mg/ dL OR

- creatinine clearance ≥ 30 mL/min (as estimated by Cockcroft Gault Equation)

- (140 - age [yrs]) (body wt [kg])

- Creatinine clearance for males = ————————————

- (72) (serum creatinine [mg/dL])

- Creatinine clearance for females = 0.85 x male value

- Women of childbearing potential (WOCBP) must use appropriate method(s) of
contraception. WOCBP should use an adequate method to avoid pregnancy for 5 months
after the last dose of investigational drug.

- Women of childbearing potential must have a negative serum or urine pregnancy test
(minimum sensitivity 25 IU/L or equivalent units of HCG) within 24 hours prior to the
start of nivolumab

- Women must not be breastfeeding

- Men who are sexually active with WOCBP must use any contraceptive method with a
failure rate of less than 1% per year. Men who are sexually active with WOCBP will be
instructed to adhere to contraception for a period of 7 months after the last dose of
investigational product. Women who are not of childbearing potential, ie, who are
postmenopausal or surgically sterile as well as azoospermic men do not require
contraception

- Ability to understand and the willingness to sign a written informed consent document

- If applicable, must be on a stable dose of dexamethasone 2 mg or less for 7 days prior
to initiation of treatment

Exclusion Criteria:

- NOTE: Patients enrolled to the randomized portion of the study (arms 1 thru 3) may not
be already treated on ACE or ARB therapy for hypertension or renal protection (with
diabetes) at the time of enrollment. If patients are receiving ACE or ARB therapy,
they may ONLY be considered for the exploratory arm, Arm 4.

- Serious concomitant systemic disorders incompatible with the study (at the discretion
of the investigator), such as significant cardiac or pulmonary morbidity e.g.
congestive heart failure, symptomatic coronary artery disease and cardiac arrhythmias
not well controlled with medication) or myocardial infarction within the last 12
months, ongoing infection as manifested by fever.

- Pregnant or lactating women. Women of childbearing potential with either a positive or
no pregnancy test (serum or urine) at baseline. (Postmenopausal women must have been
amenorrheic for at least 12 months to be considered of non-childbearing potential.)

- Any prior chemotherapy, radiation therapy, immunotherapy, or biologic ('targeted')
therapy for treatment of the patient's pancreatic tumor

- Treatment for other invasive carcinomas within the last five years who are at greater
than 5% risk of recurrence at time of eligibility screening. Carcinoma in-situ and
basal cell carcinoma/ squamous cell carcinoma of the skin are allowed.

- Lack of physical integrity of the upper gastrointestinal tract or malabsorption
syndrome

- Known, existing uncontrolled coagulopathy

- Prior systemic fluoropyrimidine therapy within the past 10 years. Prior topical
fluoropyrimidine use is allowed. Prior unanticipated severe reaction to
fluoropyrimidine therapy, or known hypersensitivity to 5-fluorouracil or known DPD
deficiency.

- Participation in any investigational drug study within 4 weeks preceding the start of
study treatment

- History of uncontrolled seizures, central nervous system disorders or psychiatric
disability judged by the investigator to be clinically significant, precluding
informed consent, or interfering with compliance or oral drug intake.

- Major surgery, excluding laparoscopy, within 4 weeks of the start of study treatment,
without complete recovery

- Concomitant use of cimetidine, as it can decrease the clearance of 5-FU. Another
H2-blocker or proton pump inhibitor may be substituted before study entry

- History of allergic reactions attributed to compounds of similar chemical or biologic
composition to 5-fluorouracil, irinotecan, oxaliplatin, or losartan

- Other serious medical conditions that the investigator feels might compromise study
participation

- An active, known or suspected autoimmune disease other than those listed below.
Subjects are permitted to enroll if they have vitiligo, type I diabetes mellitus,
residual hypothyroidism due to autoimmune condition only requiring hormone
replacement, psoriasis not requiring systemic treatment, or conditions not expected to
recur in the absence of an external trigger

- A condition requiring systemic treatment with either corticosteroids (> 15 mg daily
prednisone equivalents) or other immunosuppressive medications within 14 days of study
drug administration. Inhaled or topical steroids and adrenal replacement doses > 15 mg
daily prednisone equivalents are permitted in the absence of active autoimmune
disease. Subjects are permitted to use topical, ocular, intra-articular, intranasal,
and inhalational corticosteroids (with minimal systemic absorption). Physiologic
replacement doses of systemic corticosteroids are permitted, even if > 10 mg/day
prednisone equivalents. A brief course of corticosteroids for prophylaxis (eg,
contrast dye allergy) or for treatment of non-autoimmune conditions (eg, delayed-type
hypersensitivity reaction caused by contact allergen) is permitted.

- Known history of active TB (Bacillus Tuberculosis)

- Known positive test for hepatitis B virus surface antigen (HBV sAg) or hepatitis C
virus ribonucleic acid (HCV antibody) indicating acute or chronic infection

- Known history of testing positive for human immunodeficiency virus (HIV) or known
acquired immunodeficiency syndrome (AIDS).

- Uncontrolled intercurrent illness including, but not limited to, ongoing or active
infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac
arrhythmia, or psychiatric illness/social situations that would limit compliance with
study requirements.

- Known psychiatric or substance abuse disorders that would interfere with cooperation
with the requirements of the trial.

- Is pregnant or breastfeeding, or expecting to conceive or father children within the
projected duration of the trial, starting with the pre-screening or screening visit
through 5 months for woman and 7 months for men, after the last dose of trial
treatment.

- Known history of, or any evidence of active, non-infectious pneumonitis

- Has received a live vaccine within 30 days of planned start of study therapy. Note:
Seasonal influenza vaccines for injection are generally inactivated flu vaccines and
are allowed; however intranasal influenza vaccines (e.g., Flu-Mist®) are live
attenuated vaccines, and are not allowed.

- History of severe hypersensitivity reaction to any monoclonal antibody